A Faster-Moving Inherited Macular Dystrophy
Sorsby fundus dystrophy is a rare inherited macular condition that tends to progress more quickly than many other macular dystrophies, typically becoming symptomatic in the 40s or 50s. It's distinguished by a specific retinal finding — a yellowish deposit along a particular layer of the eye called Bruch's membrane — and by its strong tendency to develop abnormal blood vessel growth beneath the retina, which is what usually drives the relatively faster vision changes compared to some other inherited macular conditions.
Night vision difficulty is often one of the earliest complaints, sometimes preceding central vision changes by years. As the condition progresses, central vision blur and distortion become more prominent, frequently accelerated by episodes of abnormal blood vessel growth beneath the macula — these episodes can cause a comparatively sudden step-down in vision, in contrast to the more gradual decline typical of several other macular dystrophies. Both eyes are usually affected, though not always perfectly in sync.
Sorsby fundus dystrophy is caused by mutations in the TIMP3 gene, which plays a role in regulating the breakdown and remodeling of Bruch's membrane, the thin layer separating the retina's support tissue from its blood supply. When TIMP3 doesn't function normally, this membrane thickens abnormally, and the altered environment appears to encourage abnormal new blood vessel growth beneath the retina — this is thought to be central to why the condition often progresses faster than other inherited macular dystrophies. Inheritance is autosomal dominant, so each child of an affected parent has roughly a 50% chance of inheriting the mutation.
A detailed retinal exam and imaging are central to diagnosis. Optical coherence tomography and fundus photography characterize the yellowish deposits along Bruch's membrane and identify any active abnormal blood vessel growth. Fluorescein or OCT angiography is often used specifically to map out these abnormal vessels when present, since detecting them early meaningfully changes management. Electroretinography can help characterize how broadly the retina is affected. Genetic testing for TIMP3 confirms the diagnosis and is useful for identifying at-risk relatives before symptoms begin.
Because abnormal blood vessel growth plays such a central role in Sorsby fundus dystrophy, anti-VEGF injection therapy — the same class of treatment used for wet age-related macular degeneration — is the primary tool for managing active episodes and is often started as soon as new vessel growth is detected. Regular monitoring, sometimes at shorter intervals than for other macular dystrophies given the faster typical pace of change, helps catch new episodes early. Low-vision rehabilitation becomes increasingly relevant as central vision declines over time.
Sorsby fundus dystrophy tends to progress more noticeably over a shorter timeframe than several other inherited macular dystrophies, particularly once abnormal blood vessel growth begins. However, anti-VEGF treatment — well established for managing this type of vessel growth in other conditions — can meaningfully slow vision loss when episodes are caught early, which is why closer monitoring is often recommended once a diagnosis is confirmed.
It's largely linked to the abnormal blood vessel growth that frequently develops beneath the retina in this condition, which can cause more sudden changes in vision compared to some other, more gradually progressive macular dystrophies.
It can be — many people with Sorsby fundus dystrophy notice night vision difficulty before significant central vision changes appear, so it's worth mentioning to an eye doctor even if daytime vision still feels normal.
Yes, particularly anti-VEGF injection therapy for episodes of abnormal blood vessel growth — this is a well-established treatment approach that can meaningfully slow further vision loss when started promptly.
It's worth discussing with a retina specialist or genetic counsellor — because the condition is dominantly inherited with roughly a 50% chance of being passed on, some families choose baseline monitoring or genetic testing for at-risk relatives even before symptoms appear.